Risk Factors Associated With Cardiovascular Events During Testosterone Administration in Older Men With Mobility Limitation.

Department of Internal Medicine, Boston University School of Medicine, 670 Albany Street, Suite 205, Boston, MA 02118. .
The Journals of Gerontology Series A Biological Sciences and Medical Sciences (Impact Factor: 4.98). 05/2012; DOI: 10.1093/gerona/gls138
Source: PubMed

ABSTRACT BACKGROUND: Testosterone in Older Men with Mobility Limitations Trial found an increased incidence of cardiovascular events in men randomized to testosterone, resulting in enrollment cessation by trial's Data and Safety Monitoring Board. We evaluated changes in gonadal hormones and markers of inflammation and coagulation to elucidate risk factors associated with cardiovascular events. METHODS: Men aged 65 years or more, with mobility limitation, total testosterone 100-350 ng/dL, or free testosterone less than 50 pg/mL, were randomized to placebo or 10 g testosterone gel daily for 6 months. Changes in total and free testosterone, estradiol and estrone, C-reactive protein, interleukin 6, fibrinogen, plasminogen activator inhibitor-1, and pro-brain naturetic peptide were compared between groups and within the testosterone group between subjects who experienced cardiovascular events and those who did not. RESULTS: Of 209 men randomized (mean age 74 years), gonadal hormones and biomarkers were available in 179 men. Baseline body mass index, gonadal hormones, lipids, Framingham risk scores, and other biomarkers were similar in the two treatment groups. Within the testosterone group, the 6-month increase in free testosterone was significantly greater in men who experienced cardiovascular events than in those who did not [mean (95% confidence interval), 10.6 (4.6-16.7) vs 5.2 (3.0-7.5) ng/dL, p = .05]. In multivariable logistic regression analysis, the change in the serum levels of free testosterone was associated with cardiovascular events. CONCLUSION: Mobility-limited older men who experienced cardiovascular events had greater increases in serum free testosterone levels than those who did not.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Observationally, men with low testosterone are more vulnerable to type 2 diabetes (T2DM). In meta-analysis of, albeit small, randomized controlled trials (RCTs) giving men testosterone improves glucose metabolism. T2DM predicts cardiovascular disease; improving glucose metabolism could be expected to reduce cardiovascular disease risk. Taken together, trials have not shown clearly that commonly used agents for glucose reduction also reduce cardiovascular risk substantially, although some treatments for T2DM, such as insulin and sulfonylureas may raise testosterone. Testosterone has never been tested as a strategy for cardiovascular disease prevention or treatment in men with T2DM. Meta-analysis of RCTs in men suggests that testosterone administration has no effect on cardiovascular events or increases cardiovascular-related events, perhaps because testosterone promotes coagulability. Regulators have warned of cardiovascular risk on testosterone and/or suggested prescription of testosterone be restricted. As such, testosterone is unlikely to be an effective means of reducing cardiovascular risk in men with T2DM.
    Current Cardiovascular Risk Reports 05/2015; 9(5). DOI:10.1007/s12170-015-0449-2
  • [Show abstract] [Hide abstract]
    ABSTRACT: Symptomatic androgen deficiency is common in patients taking opioid analgesics, as these drugs potently suppress the hypothalamic-pituitary-gonadal axis. However, the efficacy of testosterone replacement in this setting remains unclear. The objective of this trial was to evaluate the efficacy of testosterone replacement on pain perception and other androgen-dependent outcomes in men with opioid-induced androgen deficiency. We conducted a randomized, double-blind, parallel placebo-controlled trial at an outpatient academic research center. Participants were men aged 18 to 64 years on opioid analgesics for chronic noncancer pain, and total testosterone levels were <350 ng/dL. Participants were randomly assigned to 14 weeks of daily transdermal gel that contained 5 g of testosterone or placebo. Primary outcomes were changes in self-reported clinical pain and objectively assessed pain sensitivity. Sexual function, quality of life, and body composition were also assessed. The mean age was 49 years. The median total and free testosterone levels at baseline were 243 ng/dL and 47 pg/mL and 251 ng/dL and 43 pg/mL in the testosterone and placebo arm, respectively. Of the 84 randomized participants, 65 had follow-up data on efficacy outcomes. Compared with men assigned to the placebo arm, those assigned to testosterone replacement experienced greater improvements in pressure and mechanical hyperalgesia, sexual desire, and role limitation due to emotional problems. Testosterone administration was also associated with an improvement in body composition. There were no between-group differences in changes in self-reported pain. In conclusion, in men with opioid-induced androgen deficiency, testosterone administration improved pain sensitivity, sexual desire, body composition, and aspects of quality of life.
    Pain 02/2015; 156(2):280-8. DOI:10.1097/01.j.pain.0000460308.86819.aa · 5.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Testosterone therapy is recommended for men with symptomatic androgen deficiency and unequivocally low testosterone levels. Although the prevalence of hypogonadism seems relatively constant, studies of prescribing patterns in both the United States and the United Kingdom show a dramatic increase in testosterone prescription in recent years, possibly due to increased marketing and inappropriate therapy. Concurrent with this, there has been growing concern regarding the potential adverse effects of testosterone therapy, particularly its cardiovascular risks. In this review, we present our current understanding of the implications of testosterone deficiency, as well as the conflicting evidence surrounding the cardiovascular effects of testosterone replacement therapy. Although there is a lack of adequate data, based on the current evidence, we conclude that testosterone therapy can be safely considered in men with appropriately diagnosed clinical androgen deficiency and increased cardiovascular risk after a thorough discussion of potential risks and with guideline recommended safety monitoring.
    Current Atherosclerosis Reports 03/2015; 17(3):490. DOI:10.1007/s11883-015-0490-0 · 3.06 Impact Factor